980 related articles for article (PubMed ID: 24352465)
21. Generating Bona Fide Mammalian Prions with Internal Deletions.
Munoz-Montesino C; Sizun C; Moudjou M; Herzog L; Reine F; Chapuis J; Ciric D; Igel-Egalon A; Laude H; Béringue V; Rezaei H; Dron M
J Virol; 2016 Aug; 90(15):6963-6975. PubMed ID: 27226369
[TBL] [Abstract][Full Text] [Related]
22. Prion Protein Devoid of the Octapeptide Repeat Region Delays Bovine Spongiform Encephalopathy Pathogenesis in Mice.
Hara H; Miyata H; Das NR; Chida J; Yoshimochi T; Uchiyama K; Watanabe H; Kondoh G; Yokoyama T; Sakaguchi S
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046443
[TBL] [Abstract][Full Text] [Related]
23. Species barrier in prion diseases: a kinetic interpretation based on the conformational adaptation of the prion protein.
Kellershohn N; Laurent M
Biochem J; 1998 Sep; 334 ( Pt 3)(Pt 3):539-45. PubMed ID: 9729459
[TBL] [Abstract][Full Text] [Related]
24. Aptamers against prion proteins and prions.
Gilch S; Schätzl HM
Cell Mol Life Sci; 2009 Aug; 66(15):2445-55. PubMed ID: 19396399
[TBL] [Abstract][Full Text] [Related]
25. Expansion of the octarepeat domain alters the misfolding pathway but not the folding pathway of the prion protein.
Leliveld SR; Stitz L; Korth C
Biochemistry; 2008 Jun; 47(23):6267-78. PubMed ID: 18473442
[TBL] [Abstract][Full Text] [Related]
26. Sc237 hamster PrPSc and Sc237-derived mouse PrPSc generated by interspecies in vitro amplification exhibit distinct pathological and biochemical properties in tga20 transgenic mice.
Yoshioka M; Imamura M; Okada H; Shimozaki N; Murayama Y; Yokoyama T; Mohri S
Microbiol Immunol; 2011 May; 55(5):331-40. PubMed ID: 21362027
[TBL] [Abstract][Full Text] [Related]
27. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
[TBL] [Abstract][Full Text] [Related]
28. Prion Infectivity Plateaus and Conversion to Symptomatic Disease Originate from Falling Precursor Levels and Increased Levels of Oligomeric PrPSc Species.
Mays CE; van der Merwe J; Kim C; Haldiman T; McKenzie D; Safar JG; Westaway D
J Virol; 2015 Dec; 89(24):12418-26. PubMed ID: 26423957
[TBL] [Abstract][Full Text] [Related]
29. Analyses of protease resistance and aggregation state of abnormal prion protein across the spectrum of human prions.
Saverioni D; Notari S; Capellari S; Poggiolini I; Giese A; Kretzschmar HA; Parchi P
J Biol Chem; 2013 Sep; 288(39):27972-85. PubMed ID: 23897825
[TBL] [Abstract][Full Text] [Related]
30. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein.
Telling GC; Scott M; Mastrianni J; Gabizon R; Torchia M; Cohen FE; DeArmond SJ; Prusiner SB
Cell; 1995 Oct; 83(1):79-90. PubMed ID: 7553876
[TBL] [Abstract][Full Text] [Related]
31. Critical significance of the region between Helix 1 and 2 for efficient dominant-negative inhibition by conversion-incompetent prion protein.
Taguchi Y; Mistica AM; Kitamoto T; Schätzl HM
PLoS Pathog; 2013; 9(6):e1003466. PubMed ID: 23825952
[TBL] [Abstract][Full Text] [Related]
32. Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein.
Liemann S; Glockshuber R
Biochemistry; 1999 Mar; 38(11):3258-67. PubMed ID: 10079068
[TBL] [Abstract][Full Text] [Related]
33. Increased infectivity of anchorless mouse scrapie prions in transgenic mice overexpressing human prion protein.
Race B; Phillips K; Meade-White K; Striebel J; Chesebro B
J Virol; 2015 Jun; 89(11):6022-32. PubMed ID: 25810548
[TBL] [Abstract][Full Text] [Related]
34. The protease-sensitive N-terminal polybasic region of prion protein modulates its conversion to the pathogenic prion conformer.
Zhang X; Pan YH; Chen Y; Pan C; Ma J; Yuan C; Yu G; Ma J
J Biol Chem; 2021 Nov; 297(5):101344. PubMed ID: 34710372
[TBL] [Abstract][Full Text] [Related]
35. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.
Meier P; Genoud N; Prinz M; Maissen M; Rülicke T; Zurbriggen A; Raeber AJ; Aguzzi A
Cell; 2003 Apr; 113(1):49-60. PubMed ID: 12679034
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the PrPc Amino-Terminal Domain in Prion Species Barriers.
Davenport KA; Henderson DM; Mathiason CK; Hoover EA
J Virol; 2016 Dec; 90(23):10752-10761. PubMed ID: 27654299
[TBL] [Abstract][Full Text] [Related]
37. Prion diseases: what is the neurotoxic molecule?
Chiesa R; Harris DA
Neurobiol Dis; 2001 Oct; 8(5):743-63. PubMed ID: 11592845
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in the histo-molecular pathology of human prion disease.
Baiardi S; Rossi M; Capellari S; Parchi P
Brain Pathol; 2019 Mar; 29(2):278-300. PubMed ID: 30588685
[TBL] [Abstract][Full Text] [Related]
39. Prions, prionoids and protein misfolding disorders.
Scheckel C; Aguzzi A
Nat Rev Genet; 2018 Jul; 19(7):405-418. PubMed ID: 29713012
[TBL] [Abstract][Full Text] [Related]
40. Unexpected tolerance of alpha-cleavage of the prion protein to sequence variations.
Oliveira-Martins JB; Yusa S; Calella AM; Bridel C; Baumann F; Dametto P; Aguzzi A
PLoS One; 2010 Feb; 5(2):e9107. PubMed ID: 20161712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
